[
    [
        {
            "time": "2023-10-01",
            "original_text": "Why Editas Medicine Stock Sank Today",
            "features": {
                "keywords": [
                    "Editas",
                    "Medicine",
                    "Stock",
                    "Sank",
                    "Today"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Editas Medicine Stock Sank Today",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie, Caribou Biosciences Ink Licensing Agreement For (CAR)-T Cell Therapeutics",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Caribou",
                    "Biosciences",
                    "Licensing",
                    "Agreement",
                    "(CAR)-T",
                    "Cell",
                    "Therapeutics"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie, Caribou Biosciences Ink Licensing Agreement For (CAR)-T Cell Therapeutics",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Caribou",
                    "Biosciences",
                    "Collaboration",
                    "License",
                    "Agreement",
                    "CAR-T",
                    "Cell",
                    "Products"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition",
            "features": {
                "keywords": [
                    "BOTOX®",
                    "FDA",
                    "Approval",
                    "Pediatric",
                    "Detrusor",
                    "Overactivity",
                    "Neurologic",
                    "Condition"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Exxon",
                    "Mobil",
                    "AbbVie",
                    "Caterpillar",
                    "Deere",
                    "&",
                    "Co",
                    "MetLife"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "healthcare",
                    "industrials",
                    "financials"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]